Skip to main content
. 2005 Jun;49(6):2260–2266. doi: 10.1128/AAC.49.6.2260-2266.2005

TABLE 4.

Microbiological outcomes at TOC visit by baseline pathogen in ME and MITT patient populations treated with linezolid or comparator drugsa

Organism and patient population % of patients cured (no. cured/total) after treatment with:
95% CI P value
Linezolid Vancomycinb
MRSA
    ME 88.6 (124/140) 66.9 (97/145) 12.38, 30.97 <0.0001
    MITT 71.0 (125/176) 55.1 (102/185) 6.08, 25.70 0.002
MSSA
    ME 84.9 (90/106) 75.3 (70/93) −1.47, 20.74 0.088
    MITT 73.0 (92/126) 66.4 (75/113) −5.02, 18.30 0.264
Streptococcus pyogenes
    ME 86.7 (13/15) 94.4 (17/18) −27.97, 12.42 0.579
    MITT 68.4 (13/19) 65.4 (17/26) −24.73, 30.81 0.915
a

TOC visits occured 7 days after the end of treatment. CI, confidence interval.

b

Patients could be switched to nafcillin, oxacillin, dicloxacillin, or flucloxacillin based on culture results.

HHS Vulnerability Disclosure